Emily Baumrin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emily Baumrin has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Alison W. Loren
Blood and Marrow Transplant, Cell Therapy and Transplant Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
6 shared publicationsEdward W. Cowen
Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, USA
6 shared publicationsJacqueline W. Mays
Oral Immunobiology Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland
4 shared publicationsSandy J. Falk
Adult Survivorship Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
4 shared publications- Stephanie J. Lee
Fred Hutchinson Cancer Center, Seattle, WA
4 shared publications Amy Forrestel
Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
3 shared publications
Latest Publications
- 9 April 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (3) , 587-609
Acute and Chronic Cutaneous Graft-versus-Host Disease: Diagnosis, Treatment, and Emerging Directions
Cutaneous graft-versus-host disease (GVHD) is a frequent manifestation after allogeneic hematopoietic stem cell transplantation. This review synthesizes classification, pathophysiology, risk factors, and diagnostic frameworks for acute and chronic cutaneous GVHD. Acute cutaneous GVHD typically presents as a morbilliform eruption, with severe cases presenting with bullae and full-thickness desquamation. Chronic cutaneous GVHD presents in more protean ways, including both nonsclerotic and sclerotic phenotypes. We review current diagnostic criteria, staging, clinical and histopathologic features, and differential diagnoses of acute and chronic cutaneous GVHD. Additionally, we summarize management across the disease continuum, including skin-directed therapy, systemic therapy, and approved therapies for steroid-refractory GVHD such as ruxolitinib and remestemcel-L for acute GVHD and ibrutinib, ruxolitinib, belumosudil, and axatilimab for chronic GVHD. We also discuss emerging therapeutic strategies and areas of active investigation in GVHD therapeutics. However, despite therapeutic advances for chronic GVHD (cGVHD), nonresponse and relapse remain common. Early dermatologic involvement to diagnose, classify, and participate in multidisciplinary management is critical to improving outcomes for patients experiencing cutaneous GVHD. Biomarker-informed risk stratification and treatment selection, mechanistically informed combination regimens, and steroid-sparing first-line approaches for GVHD treatment are research priorities to enhance efficacy while minimizing toxicity.
- 9 April 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (3) , 587-609
Acute and Chronic Cutaneous Graft-versus-Host Disease: Diagnosis, Treatment, and Emerging Directions
Cutaneous graft-versus-host disease (GVHD) is a frequent manifestation after allogeneic hematopoietic stem cell transplantation. This review synthesizes classification, pathophysiology, risk factors, and diagnostic frameworks for acute and chronic cutaneous GVHD. Acute cutaneous GVHD typically presents as a morbilliform eruption, with severe cases presenting with bullae and full-thickness desquamation. Chronic cutaneous GVHD presents in more protean ways, including both nonsclerotic and sclerotic phenotypes. We review current diagnostic criteria, staging, clinical and histopathologic features, and differential diagnoses of acute and chronic cutaneous GVHD. Additionally, we summarize management across the disease continuum, including skin-directed therapy, systemic therapy, and approved therapies for steroid-refractory GVHD such as ruxolitinib and remestemcel-L for acute GVHD and ibrutinib, ruxolitinib, belumosudil, and axatilimab for chronic GVHD. We also discuss emerging therapeutic strategies and areas of active investigation in GVHD therapeutics. However, despite therapeutic advances for chronic GVHD (cGVHD), nonresponse and relapse remain common. Early dermatologic involvement to diagnose, classify, and participate in multidisciplinary management is critical to improving outcomes for patients experiencing cutaneous GVHD. Biomarker-informed risk stratification and treatment selection, mechanistically informed combination regimens, and steroid-sparing first-line approaches for GVHD treatment are research priorities to enhance efficacy while minimizing toxicity.
- 17 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (1) , e15-e16
Skin cancer screening in blind and visually impaired patients
- 17 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (1) , e15-e16
Skin cancer screening in blind and visually impaired patients
- 11 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (6) , 1803-1805
Chronic graft-versus-host disease has similar or worse impact on skin-specific quality of life than autoimmune connective tissue diseases: A cross-sectional study
- 11 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (6) , 1803-1805
Chronic graft-versus-host disease has similar or worse impact on skin-specific quality of life than autoimmune connective tissue diseases: A cross-sectional study
- Open Access
- 14 January 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (6) , 644.e1-644.e19
Toward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force
- 14 January 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (6) , 644.e1-644.e19
Open AccessToward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force
- 5 August 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (9) , 1-11
Vitamin C deficiency in allogeneic hematopoietic cell transplantation recipients in the peri-transplant period
Purpose Hypovitaminosis C is observed in patients with hematologic malignancy, including those receiving hematopoietic cell transplantation (HCT). This study examines longitudinal vitamin C levels and inflammatory markers in patients receiving allogeneic HCT and determines the impact of treated hypovitaminosis C prior to conditioning on clinical outcomes, including mucositis. Methods Adults were prospectively enrolled at the time of admission for allogeneic HCT. Clinical outcomes were compared between patients with normal vitamin C, hypovitaminosis C, and indeterminate vitamin C due to acute inflammation prior to conditioning. Patients with hypovitaminosis C were given ascorbic acid supplementation at standard dosages. Results Sixty patients were enrolled (37 [62%] male, median age 61 years [range 22–75]), 19 (32%) with hypovitaminosis C, 28 (47%) with normal vitamin C, and 13 (22%) with indeterminate vitamin C stores due to the presence of inflammation (CRP). Patients with baseline hypovitaminosis C receiving standard dose supplementation had no difference in mucositis outcomes compared to patients with baseline normal vitamin C (adjusted odds ratio [aOR] grade III/IV mucositis=2.64 [0.44–17.96], p=0.29 and aOR hemorrhagic mucositis=0.50 [0.12–1.86], p=0.30) but did have higher odds of persistent hypovitaminosis C after discharge despite supplementation (aOR 3.71 [CI 1.05–14.22], p=0.04). Patients with high baseline CRP had higher odds of grade III/IV mucositis (aOR 8.06 [1.27–74.31], p=0.03), hemorrhagic mucositis (aOR 4.78 [1.09–25.46], p=0.04), and post-discharge hypovitaminosis C (aOR 17.80 [3.04–196.41], p=0.001). Conclusion Hypovitaminosis C is prevalent prior to allogeneic HCT. Patients with hypovitaminosis C treated with standard ascorbic acid repletion had no difference in clinical outcomes compared to patients with normal vitamin C levels; however, repletion was not sufficient to restore normal vitamin C levels. Patients with high baseline CRP and thus indeterminate vitamin C stores had worse clinical outcomes overall including severe mucositis. Optimal timing and dosing of vitamin C supplementation should be determined.
- 5 August 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (9) , 1-11
Vitamin C deficiency in allogeneic hematopoietic cell transplantation recipients in the peri-transplant period
Purpose Hypovitaminosis C is observed in patients with hematologic malignancy, including those receiving hematopoietic cell transplantation (HCT). This study examines longitudinal vitamin C levels and inflammatory markers in patients receiving allogeneic HCT and determines the impact of treated hypovitaminosis C prior to conditioning on clinical outcomes, including mucositis. Methods Adults were prospectively enrolled at the time of admission for allogeneic HCT. Clinical outcomes were compared between patients with normal vitamin C, hypovitaminosis C, and indeterminate vitamin C due to acute inflammation prior to conditioning. Patients with hypovitaminosis C were given ascorbic acid supplementation at standard dosages. Results Sixty patients were enrolled (37 [62%] male, median age 61 years [range 22–75]), 19 (32%) with hypovitaminosis C, 28 (47%) with normal vitamin C, and 13 (22%) with indeterminate vitamin C stores due to the presence of inflammation (CRP). Patients with baseline hypovitaminosis C receiving standard dose supplementation had no difference in mucositis outcomes compared to patients with baseline normal vitamin C (adjusted odds ratio [aOR] grade III/IV mucositis=2.64 [0.44–17.96], p=0.29 and aOR hemorrhagic mucositis=0.50 [0.12–1.86], p=0.30) but did have higher odds of persistent hypovitaminosis C after discharge despite supplementation (aOR 3.71 [CI 1.05–14.22], p=0.04). Patients with high baseline CRP had higher odds of grade III/IV mucositis (aOR 8.06 [1.27–74.31], p=0.03), hemorrhagic mucositis (aOR 4.78 [1.09–25.46], p=0.04), and post-discharge hypovitaminosis C (aOR 17.80 [3.04–196.41], p=0.001). Conclusion Hypovitaminosis C is prevalent prior to allogeneic HCT. Patients with hypovitaminosis C treated with standard ascorbic acid repletion had no difference in clinical outcomes compared to patients with normal vitamin C levels; however, repletion was not sufficient to restore normal vitamin C levels. Patients with high baseline CRP and thus indeterminate vitamin C stores had worse clinical outcomes overall including severe mucositis. Optimal timing and dosing of vitamin C supplementation should be determined.
- Open Access
- 31 March 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 65, 112-115
Cytomegalovirus anogenital ulcers in an immunosuppressed patient
- 31 March 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 65, 112-115
Open AccessCytomegalovirus anogenital ulcers in an immunosuppressed patient
- 20 March 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (12) , 1321-1332
Development of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosis
Sclerosis is a highly morbid manifestation of chronic graft-versus-host disease (cGVHD), associated with distressing symptoms and significant long-term disability. A patient-reported outcome (PRO) measure for cGVHD-associated sclerosis is essential to advance therapeutic trials. We aimed to develop a PRO for adults with cGVHD-associated sclerosis and evaluate and refine its content validity. Adults aged ≥18 years with cGVHD-associated sclerosis participated in semistructured interviews to identify salient symptoms and functions. Sclerosis-relevant symptoms and functions from existing PROs were also used to prompt discussion of topics not spontaneously mentioned. Symptoms and functions (subcodes) of importance were clustered and mapped to overarching domains (codes) using inductive analysis, and candidate items were developed. Cognitive interviews were used to evaluate content validity of the items, response options, recall period, and respondent instructions. Thirty-six open-ended interviews, conducted to saturation, revealed the breadth of the patient experience with cGVHD-associated sclerosis including 5 overarching domains: (1) skin changes, (2) symptoms, (3) emotional and social functioning, (4) mobility restrictions, and (5) activity limitations. A pool of 54 items was tested and iteratively refined through cognitive debriefing interviews (n = 25). Phrasing changes were made to improve relevance and comprehension. One item was removed, and 2 items were added to address respondent feedback, resulting in 55 items. Results support the relevance, comprehensibility, and comprehensiveness of the provisional Lee Symptom Scale–Skin Sclerosis. Concept elicitation and cognitive interviewing have informed the development of the Lee Symptom Scale–Skin Sclerosis. Psychometric testing and determination of minimal clinically important differences are underway in an external cohort to validate the PROs.
- 20 March 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (12) , 1321-1332
Development of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosis
Sclerosis is a highly morbid manifestation of chronic graft-versus-host disease (cGVHD), associated with distressing symptoms and significant long-term disability. A patient-reported outcome (PRO) measure for cGVHD-associated sclerosis is essential to advance therapeutic trials. We aimed to develop a PRO for adults with cGVHD-associated sclerosis and evaluate and refine its content validity. Adults aged ≥18 years with cGVHD-associated sclerosis participated in semistructured interviews to identify salient symptoms and functions. Sclerosis-relevant symptoms and functions from existing PROs were also used to prompt discussion of topics not spontaneously mentioned. Symptoms and functions (subcodes) of importance were clustered and mapped to overarching domains (codes) using inductive analysis, and candidate items were developed. Cognitive interviews were used to evaluate content validity of the items, response options, recall period, and respondent instructions. Thirty-six open-ended interviews, conducted to saturation, revealed the breadth of the patient experience with cGVHD-associated sclerosis including 5 overarching domains: (1) skin changes, (2) symptoms, (3) emotional and social functioning, (4) mobility restrictions, and (5) activity limitations. A pool of 54 items was tested and iteratively refined through cognitive debriefing interviews (n = 25). Phrasing changes were made to improve relevance and comprehension. One item was removed, and 2 items were added to address respondent feedback, resulting in 55 items. Results support the relevance, comprehensibility, and comprehensiveness of the provisional Lee Symptom Scale–Skin Sclerosis. Concept elicitation and cognitive interviewing have informed the development of the Lee Symptom Scale–Skin Sclerosis. Psychometric testing and determination of minimal clinically important differences are underway in an external cohort to validate the PROs.
- 1 March 2025
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 161 (3) , 281
Outcomes of Importance to Patients Living With Cutaneous Chronic Graft-vs-Host Disease
Importance: Cutaneous chronic graft-vs-host disease (GVHD) is independently associated with morbidity and mortality after allogeneic hematopoietic cell transplant. However, the health-related quality-of-life (HRQOL) domains that are most important to patients are poorly understood.Objective: To perform a concept elicitation study to define HRQOL in cutaneous chronic GVHD from the patient perspective and to compare experiences of patients with epidermal vs sclerotic disease.Design, Setting, and Participants: A single-center qualitative analysis from open-ended, semistructured interviews and free-listing terms conducted between April and September 2023. Participants were 18 years or older with a diagnosis of active cutaneous chronic GVHD, purposefully sampled for epidermal and sclerotic disease features, with ongoing sampling until thematic saturation.Main Outcomes: HRQOL domains and codes from patient perspectives of living with cutaneous chronic GVHD were identified by inductive analysis of semistructured interviews. Smith salience index (Smith S) score, a measure of saliency for each list term, was calculated from free-listing terms from deidentified patient interviews.Results: A total of 31 adults with cutaneous chronic GVHD (median [IQR] age, 61.1 [52.9-68.7] years) participated in interviews; 17 participants (54.8%) were male and 14 (45.2%) were female. Nine participants (29.0%) had epidermal, 13 (41.9%) sclerotic, and 9 (29.0%) a combination of disease types. The study identified 40 codes of importance grouped within 5 HRQOL domains: skin changes and symptoms, social functioning, psychological and emotional functioning, physical functioning, and general health perceptions. The most frequent symptoms were dry skin (n = 20 [65%]), tight skin (n = 19 [61%]), itch (n = 15 [48%]), and discoloration (n = 14 [45%]), which were seen in all disease subtypes. Impairment in social functioning was noted by all participants. Psychological and emotional functioning, including frustration (Smith S score, 0.32) and worry or concern (Smith S score, 0.12), and symptoms including discomfort (Smith S score, 0.20) were the most salient to patients. Individual and environmental factors, such as social comparison, illness comparison with cancer, anatomic location of disease involvement, and disease duration, affected the relationship between skin changes and symptoms and downstream functioning and general health perceptions.Conclusions and Relevance: This qualitative analysis demonstrated the direct relationship between cutaneous chronic GVHD and HRQOL domains and identified codes not represented in existing GVHD- and dermatology-specific patient-reported outcome measures. These results can guide patient-reported outcome development and instrument selection for clinical trials and improve clinical decision-making.
- 1 March 2025
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 161 (3) , 281
Outcomes of Importance to Patients Living With Cutaneous Chronic Graft-vs-Host Disease
Importance: Cutaneous chronic graft-vs-host disease (GVHD) is independently associated with morbidity and mortality after allogeneic hematopoietic cell transplant. However, the health-related quality-of-life (HRQOL) domains that are most important to patients are poorly understood.Objective: To perform a concept elicitation study to define HRQOL in cutaneous chronic GVHD from the patient perspective and to compare experiences of patients with epidermal vs sclerotic disease.Design, Setting, and Participants: A single-center qualitative analysis from open-ended, semistructured interviews and free-listing terms conducted between April and September 2023. Participants were 18 years or older with a diagnosis of active cutaneous chronic GVHD, purposefully sampled for epidermal and sclerotic disease features, with ongoing sampling until thematic saturation.Main Outcomes: HRQOL domains and codes from patient perspectives of living with cutaneous chronic GVHD were identified by inductive analysis of semistructured interviews. Smith salience index (Smith S) score, a measure of saliency for each list term, was calculated from free-listing terms from deidentified patient interviews.Results: A total of 31 adults with cutaneous chronic GVHD (median [IQR] age, 61.1 [52.9-68.7] years) participated in interviews; 17 participants (54.8%) were male and 14 (45.2%) were female. Nine participants (29.0%) had epidermal, 13 (41.9%) sclerotic, and 9 (29.0%) a combination of disease types. The study identified 40 codes of importance grouped within 5 HRQOL domains: skin changes and symptoms, social functioning, psychological and emotional functioning, physical functioning, and general health perceptions. The most frequent symptoms were dry skin (n = 20 [65%]), tight skin (n = 19 [61%]), itch (n = 15 [48%]), and discoloration (n = 14 [45%]), which were seen in all disease subtypes. Impairment in social functioning was noted by all participants. Psychological and emotional functioning, including frustration (Smith S score, 0.32) and worry or concern (Smith S score, 0.12), and symptoms including discomfort (Smith S score, 0.20) were the most salient to patients. Individual and environmental factors, such as social comparison, illness comparison with cancer, anatomic location of disease involvement, and disease duration, affected the relationship between skin changes and symptoms and downstream functioning and general health perceptions.Conclusions and Relevance: This qualitative analysis demonstrated the direct relationship between cutaneous chronic GVHD and HRQOL domains and identified codes not represented in existing GVHD- and dermatology-specific patient-reported outcome measures. These results can guide patient-reported outcome development and instrument selection for clinical trials and improve clinical decision-making.